Ipsen S.A. ADR (IPSEY) 11.2930 $IPSEY
Ipsen Announces Name Change for its Research and Development Affiliate in the U.S. From Biomeasure to Ipsen Bioscience, Inc.
Business Wire - Tue May 06, 9:17AM CDT
The U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced that, as of May 1, 2014, its U.S. Research and Development (R&D) affiliate, previously called Biomeasure, has changed its name to Ipsen Bioscience, Inc. The change is being made to strengthen the Ipsen brand in the U.S. by unifying the commercial group, Ipsen Biopharmaceuticals, Inc., with the research and development (R&D) group, Ipsen Bioscience, Inc., under the Ipsen brand.
Ipsen's first quarter 2014 sales
Business Wire - Wed Apr 30, 12:00AM CDT
--Solid specialty care growth, up 6.4%(1)
Ipsen eligible for PEA-PME and included in CAC(R) PME index by Euronext
Business Wire - Wed Apr 09, 1:00AM CDT
Regulatory News:
Ipsen's net profit up by 6.4% in H1 2013
M2 - Fri Aug 30, 7:59AM CDT
Ipsen SA (Euronext: IPN) (Paris: IPN.PA), a specialty-driven pharmaceutical company, on Friday reported consolidated net profit attributable to shareholders of EUR96.2m, or diluted EPS of EUR1.15, for the first half 2013, ended 30 June 2013.
Baxter closes deal for potential hemophilia drug
By The Associated Press - AP - Thu Mar 21, 8:39AM CDT
Baxter International Inc. has closed its acquisition of a potential hemophilia treatment from the French drugmaker Ipsen and Inspiration Biopharmaceuticals Inc. in a deal that could be worth more than $180 million.
Ipsen Announces Name Change for its Research and Development Affiliate in the U.S. From Biomeasure to Ipsen Bioscience, Inc.
Business Wire - Tue May 06, 9:17AM CDT
The U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced that, as of May 1, 2014, its U.S. Research and Development (R&D) affiliate, previously called Biomeasure, has changed its name to Ipsen Bioscience, Inc. The change is being made to strengthen the Ipsen brand in the U.S. by unifying the commercial group, Ipsen Biopharmaceuticals, Inc., with the research and development (R&D) group, Ipsen Bioscience, Inc., under the Ipsen brand.
Ipsen's first quarter 2014 sales
Business Wire - Wed Apr 30, 12:00AM CDT
--Solid specialty care growth, up 6.4%(1)
Ipsen eligible for PEA-PME and included in CAC(R) PME index by Euronext
Business Wire - Wed Apr 09, 1:00AM CDT
Regulatory News:
Ipsen's net profit up by 6.4% in H1 2013
M2 - Fri Aug 30, 7:59AM CDT
Ipsen SA (Euronext: IPN) (Paris: IPN.PA), a specialty-driven pharmaceutical company, on Friday reported consolidated net profit attributable to shareholders of EUR96.2m, or diluted EPS of EUR1.15, for the first half 2013, ended 30 June 2013.
Baxter closes deal for potential hemophilia drug
By The Associated Press - AP - Thu Mar 21, 8:39AM CDT
Baxter International Inc. has closed its acquisition of a potential hemophilia treatment from the French drugmaker Ipsen and Inspiration Biopharmaceuticals Inc. in a deal that could be worth more than $180 million.
